SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
tina
Lv1
80 积分
2024-04-09 加入
最近求助
最近应助
互助留言
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer
6天前
已关闭
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
9天前
已完结
A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
11天前
已完结
A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
11天前
已完结
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
11天前
已完结
Cardiovascular toxicity of immune therapies for cancer
13天前
已完结
Bispecific antibodies: a mechanistic review of the pipeline
17天前
已完结
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma
17天前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
17天前
已完结
Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
20天前
已关闭
没有进行任何应助
点赞,感谢,速度真快,帮大忙了,么么哒
9天前
感谢,点赞,速度真快,帮大忙了,么么哒
9天前
感谢,点赞,速度真快,帮大忙了,么么哒
11天前
感谢,点赞,速度真快,帮大忙了,么么哒
11天前
感谢,点赞,速度真快,帮大忙了,么么哒
13天前
感谢,点赞,速度真快,帮大忙了,么么哒
17天前
感谢,点赞,速度真快,帮大忙了,么么哒
17天前
感谢,点赞,速度真快,帮大忙了,么么哒
17天前
感谢,点赞,速度真快,帮大忙了,么么哒
23天前
感谢,点赞,速度真快,帮大忙了,么么哒
25天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论